Terminated NA INTERVENTIONAL 2-arm NCT05965401

Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents (PGx-GAP)

Pharmacogenetic-Guided Antidepressant Prescribing (PGx-GAP) in Adolescents

Sponsor: University of Alberta

Interventions GLAD-PC guided dosing Pharmacogenetic-guided dosing

Updated 6 times since 2023 Last updated: May 14, 2025 Started: Oct 25, 2023 Primary completion: May 2, 2025 Completion: May 2, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low recruitment

Other terminated trials from University of Alberta

See all terminations from University of Alberta

This NA trial investigates Depression in Adolescence and is currently terminated or withdrawn. University of Alberta leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Jun 2025 — Present [monthly]

Terminated NA

Status: Recruiting → Terminated
Dec 2024 — Jun 2025 [monthly]

Recruiting NA
Sep 2024 — Dec 2024 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Nov 2023 — Jul 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Aug 2023 — Nov 2023 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Alberta
University of Calgary

Data source: University of Calgary

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Calgary, Canada